论文部分内容阅读
应用可选择性杀灭的瘤细胞和淋巴瘤细胞混合培养的体外致敏方法，从急性Ｔ细胞（Ｌ６１５）白血病小鼠的脾细胞中建立了体外可培养的肿瘤特异性反应Ｔ细胞系（ＴＳＲＴｓ）。细胞表型分析和功能测定的结果表明，这些ＴＳＲＴｓ中是以表型ＣＤ４＋Ｔ细胞为主（占７５％以上）。对结合Ｌ６１５瘤细胞膜蛋白的硝酸纤维素薄膜颗粒的刺激呈特异性反应，并对Ｌ６１５瘤细胞刺激反应产生白细胞介素２。虽然体外缺乏急性溶细胞活性，但Ｗｉｎｎ’ｓ测定和继承性免疫治疗结果表明体内转输这些ＣＤ４＋为主的ＴＳＲＴｓ具有显著抗瘤活性，与ＣＹ联合可以明显延长Ｌ６１５白血病小鼠存活时间。提示ＣＤ４＋ＴＳＲＴｓ在控制体内白血病细胞发展中可能起重要作用
An in vitro culturable tumor-specific T cell line was established from the splenocytes of acute T cell (L615) leukemia mice by in vitro sensitization using a mixture of selectively killed tumor cells and lymphoid tumor cells TSRTs). The results of cell phenotype analysis and functional assay showed that the majority of these TSRTs were phenotypic CD4 + T cells (accounting for more than 75%). Specific responses to stimulation of the nitrocellulose membrane particles that bound the L615 tumor cell membrane protein and production of interleukin 2 on the L615 tumor cell stimulus response. Despite the lack of acute cytolytic activity in vitro, the results of Winn’s assay and adoptive immunotherapy showed that the transfection of these CD4 + -based TSRTs in vivo has significant antitumor activity. Combined with CY can significantly prolong the survival of L615 leukemia mice. These results suggest that CD4 + TSRTs may play an important role in the control of the development of leukemic cells in vivo